NDA 213051 · Novo
Ozempic
Semaglutide · Oral · GLP-1 Receptor Agonist
Priority reviewLast checked: Nov 20, 2026Latest source record: Jan 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Sep 20, 2019
Approved uses
3
Original approval plus efficacy supplements
Registered trials
626
187 Phase 3, 161 recruiting
FAERS reports
78,023
39,105 serious, 1,364 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether RYBELSUS and OZEMPIC tablets cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . • RYBELSUS and OZEMPIC tablets are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of RYBELSUS or OZEMPIC tablets and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent...
What it is approved for
From the label in effect Jan 30, 2026.
RYBELSUS and OZEMPIC tablets are indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. RYBELSUS and OZEMPIC tablets are glucagon-like peptide-1 (GLP-1) receptor agonists indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. ( 1 )
Mechanism: Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 17, 2025 Supplement 24 · Efficacy LabelMedication GuideLetter
- Dec 9, 2024 Supplement 20 · Efficacy LabelLetter
- Sep 20, 2019 Original approval · Type 3 - New Dosage Form · priority review LabelLetterReview
6 products under this application
- OZEMPIC · SEMAGLUTIDE 9MG · TABLET, ORAL · Prescription
- OZEMPIC · SEMAGLUTIDE 1.5MG · TABLET, ORAL · Prescription
- RYBELSUS · SEMAGLUTIDE 7MG · TABLET, ORAL · Prescription
- OZEMPIC · SEMAGLUTIDE 4MG · TABLET, ORAL · Prescription
- RYBELSUS · SEMAGLUTIDE 14MG · TABLET, ORAL · Prescription
- RYBELSUS · SEMAGLUTIDE 3MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Semaglutide" as an intervention, any sponsor and status, largest first.
- A Study of Cardiovascular Events iN Diabetes PlusPivotal-lookingActive, not recruiting
University of OxfordAcademic, hospital or other
NCT05441267 · 21,296 participants · Start Mar 13, 2023 · Primary completion Aug 17, 2028
Drug: Semaglutide Oral Tablet; Placebo oral tablet · For: Diabetes Mellitus, Type 2
Sites: Oxford, United Kingdom
- Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03574597 · 17,604 participants · Start Oct 24, 2018 · Primary completion Jun 21, 2023
Drug: Semaglutide; Placebo (semaglutide) · For: Overweight; Obesity
Sites: Birmingham, Alabama; Montgomery, Alabama; Glendale, Arizona · 833 sites in all
- A Heart Disease Study of Semaglutide in Patients With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03914326 · 9,651 participants · Start Jun 17, 2019 · Primary completion Aug 23, 2024
Drug: Semaglutide; Placebo (semaglutide) · For: Diabetes Mellitus, Type 2
Sites: Montgomery, Alabama; Little Rock, Arkansas; Searcy, Arkansas · 492 sites in all
- REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05669755 · 7,101 participants · Start Mar 1, 2023 · Primary completion Sep 1, 2027
Drug: Cagrilintide; Semaglutide and 1 more · For: Cardiovascular Disease
Sites: Birmingham, Alabama; Montgomery, Alabama; Scottsdale, Arizona · 633 sites in all
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT05390892 · 6,000 participants (planned) · Start Sep 26, 2022 · Primary completion Mar 1, 2029
Drug: SGLT2 inhibitor; GLP-1 receptor agonist · For: Type2Diabetes; ASCVD
Sites: Huntsville, Alabama; Scottsdale, Arizona; Los Angeles, California · 36 sites in all
- A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney DiseasePivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03819153 · 3,533 participants · Start Jun 17, 2019 · Primary completion Jan 9, 2024
Drug: Semaglutide; Placebo (semaglutide) · For: Diabetes Mellitus, Type 2
Sites: Tuscumbia, Alabama; Chula Vista, California; Concord, California · 413 sites in all
- A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05567796 · 3,400 participants (planned) · Start Nov 1, 2022 · Primary completion Oct 30, 2024
Drug: Cagrilintide; Semaglutide and 2 more · For: Obesity
Sites: Birmingham, Alabama; Los Angeles, California; Aurora, Colorado · 256 sites in all
- Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01720446 · 3,297 participants · Start Feb 21, 2013 · Primary completion Mar 15, 2016
Drug: semaglutide; semaglutide and 1 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Chandler, Arizona; Anaheim, California · 253 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea11,150
- off label use7,890
- vomiting7,332
- diarrhoea6,833
- decreased appetite5,107
- constipation4,976
- weight decreased4,777
- impaired gastric emptying4,175
- product use in unapproved indication3,761
- blood glucose increased3,460
- fatigue3,252
- headache3,240
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 7 |
| 2016 | 14 |
| 2017 | 14 |
| 2018 | 1,142 |
| 2019 | 1,596 |
| 2020 | 3,514 |
| 2021 | 4,563 |
| 2022 | 6,320 |
| 2023 | 9,506 |
| 2024 | 14,313 |
| 2025 | 20,019 |
| 2026 | 17,010 |
Recalls
1 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Jun 4, 2026
Rybelsus, Tablet, 3 mg (NDC 0169-4303-30). Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
To Be Discontinued · updated Jun 4, 2026
Rybelsus, Tablet, 7 mg (NDC 0169-4307-30). Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
To Be Discontinued · updated Jun 4, 2026
Rybelsus, Tablet, 14 mg (NDC 0169-4314-30). Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ozempic (Semaglutide)
2024 spending
$13.0B
Beneficiaries
1,952,637
10,417,182 claims
Per beneficiary
$6,642
$306.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,455,812,267 |
| 2021 | $2,621,694,348 |
| 2022 | $4,628,160,643 |
| 2023 | $9,194,048,435 |
| 2024 | $12,970,296,347 |
Part D: Rybelsus (Semaglutide)
2024 spending
$1.89B
Beneficiaries
309,993
1,251,733 claims
Per beneficiary
$6,097
$30.59 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $73,444,409 |
| 2021 | $454,563,823 |
| 2022 | $974,894,470 |
| 2023 | $1,665,906,943 |
| 2024 | $1,890,082,026 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Aronne LJ, Horn DB, le Roux CW, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Comparative Study
- Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.
Heise T, DeVries JH, Urva S, et al. · Diabetes Care 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Wilding JPH, Batterham RL, Davies M, et al. · Diabetes Obes Metab 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, et al. · N Engl J Med 2021 · Multicenter Study, Randomized Controlled Trial
- Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.
Tan B, Pan XH, Chew HSJ, et al. · Int J Obes (Lond) 2023 · Meta-Analysis, Systematic Review
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · N Engl J Med 2023 · Equivalence Trial, Multicenter Study
Sponsor: Novo · Also marketed as Rybelsus
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.